Biostage (OTCMKTS:BSTG) Releases Earnings Results

Biostage (OTCMKTS:BSTG) posted its quarterly earnings data on Tuesday. The company reported ($0.37) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.

OTCMKTS:BSTG opened at $2.30 on Friday. The company has a current ratio of 1.81, a quick ratio of 1.81 and a debt-to-equity ratio of 0.03. Biostage has a 52-week low of $0.75 and a 52-week high of $3.75. The stock has a 50-day simple moving average of $2.25 and a 200 day simple moving average of $2.40.

Separately, ValuEngine upgraded Biostage from a “hold” rating to a “buy” rating in a report on Thursday, August 1st.

Biostage Company Profile

Biostage, Inc, a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities.

Further Reading: Operating Income

Earnings History for Biostage (OTCMKTS:BSTG)

Receive News & Ratings for Biostage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage and related companies with MarketBeat.com's FREE daily email newsletter.